close
MENU
How to guide
How to guide
Home
The NBR List
NBR View
NBR Marketplace

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

Podcasts Audio Articles Entrepreneurs Your Business Beehive Banter Morning Brew Toil & Trouble NZ Aviation News Back Issues Market Outlook Dollars & Sense Private Bin Opinion (Archive) NBR Radar (Archive) NBR Rich List (Archive)
General Business
4 mins to read

New Zealand cannabis industry ripe for big pharma acquisitions

MedCan Summit lays out expectations on the industry’s future.

Andrew Bevin Thu, 10 Feb 2022

Consolidation is the future of the medical cannabis industry, according to today’s speakers at the national industry summit, MedCan 2022.

During a chief executive panel event at the conference, NZX-listed Rua Bioscience co-founder Manu Caddie (standing in for CEO Rob Mitchell) said he expected

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Andrew Bevin Thu, 10 Feb 2022
Contact the Writer: andrew@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
medical cannabis pharmaceuticals Rua Bioscience
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
Law
6

Medical Kiwi admits false statements made in $2m crowdfunding
Investment
1

Rua has first cannabis product approved
Investment
3

Rua purchases Zalm in $10m equity deal
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
Law
6

Medical Kiwi admits false statements made in $2m crowdfunding
Investment
1

Rua has first cannabis product approved
Investment
3

Rua purchases Zalm in $10m equity deal
New Zealand cannabis industry ripe for big pharma acquisitions
General Business,
90450
true
Subscribe Login